Leveraging the versatility of pox virus vectors and their historical success in previous viral eradication programs (e.g. small pox), Therion is investigating opportunities to produce vaccines for serious infectious diseases. Therion is currently developing a family of preventive AIDS vaccines in a program supported through a series of grants and contracts from National Institutes of Health and the International AIDS Vaccine Initiative. Therion's vaccines combine multiple viral antigens to elicit a full range of antibody and cellular immune responses, and are designed to achieve the efficacy of live attenuated HIV vaccines with the safety of Therion's recombinant pox virus-based products. Therion collaborates with several national and international institutions, including the International AIDS Vaccine Initiative (IAVI), with whom Therion is developing an AIDS vaccine for India.
|
|
||||||||||
|
PRODUCT CANDIDATES The Company has four vaccine candidates in development. TBC-3B, Therion�s first AIDS vaccine, has exhibited a strong safety profile to date in Phase I studies. Therion is currently developing a new generation of multi-antigen AIDS vaccines based on an additional pox virus vector designated MVA. Therion expects these vaccines to enter Phase I clinical trial in cooperation with the NIH.
|
|||||||||||
